The present invention relates to a compound of formula (I), wherein L is -C(O)NH-, -NHC(O)-, -S(O)2NH-, -NH- or -NHC(O)NH- Ar is phenyl, benzyl, naphthyl or heteroaryl, selected from the group consisting of pyridinyl, pyrazolyl, pyrimidinyl, isoxazolyl or pyrazinyl, wherein Ar may be optionally substituted by one, two or three R1 R1 is hydrogen, lower alkyl, lower alkoxy, halogen, cyano, cycloalkyl, NHC(O)-lower alkyl, lower alkoxy substituted by halogen, lower alkyl substituted by halogen, or is phenyl optionally substituted by one or two halogen atoms, CF3O or lower alkyl, or is furanyl, thiazolyl or thiophenyl, optionally substituted by halogen or lower alkyl X is CH or O R is hydrogen or halogen or a pharmaceutically suitable acid addition salt thereof, all racemic mixtures, all their corresponding enantiomers and/or optical isomers, which may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinsons disease, neurodegenerative disorders, Alzheimers disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.La presente invención hace referencia a un compuesto con la fórmula (ver Fórmula) I, en la que L es -C(O)NH-, -NHC(O)-, -S O)2NH-, -NH- o -NHC (O) NH- Ar es fenilo, bencilo, naftilo o un heteroarilo, que se selecciona a partir del grupo que incluye piridinilo, pirazolilo, pirimidinilo, isoxazolilo o pirazinilo, en el que Ar puede sustituirse de manera opcional por uno, dos o tres R1 R1 es hidrógeno, un alquilo inferior, un alcoxi inferior, un halógeno, ciano, cicloalquilo, un alquilo-NHC(O) inferior, un alcoxi inferior sustitui
